Theravance Biopharma, Inc. (NASDAQ:TBPH) Given Consensus Recommendation of "Moderate Buy" by Analysts

Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the six research firms that are currently covering the firm, MarketBeat reports. Three analysts have rated the stock with a hold recommendation, two have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $16.60.

TBPH has been the topic of a number of research analyst reports. Wall Street Zen lowered shares of Theravance Biopharma from a "buy" rating to a "hold" rating in a report on Saturday. Jones Trading upgraded shares of Theravance Biopharma to a "strong-buy" rating and set a $24.00 target price for the company in a research report on Tuesday, June 17th. Finally, BTIG Research raised their price target on Theravance Biopharma from $24.00 to $25.00 and gave the company a "buy" rating in a research report on Friday, June 27th.

Theravance Biopharma Stock Performance

NASDAQ:TBPH opened at $11.30 on Friday. Theravance Biopharma has a 52-week low of $7.44 and a 52-week high of $11.82. The stock has a fifty day moving average of $10.30 and a 200 day moving average of $9.60. The firm has a market capitalization of $565 million, a price-to-earnings ratio of -9.58 and a beta of -0.02.

Theravance Biopharma (NASDAQ:TBPH - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.16). The business had revenue of $15.39 million for the quarter, compared to the consensus estimate of $28.08 million. Theravance Biopharma had a negative net margin of 89.38% and a negative return on equity of 32.37%. Equities analysts forecast that Theravance Biopharma will post -1.09 earnings per share for the current fiscal year.

Insider Activity

In other news, SVP Rhonda Farnum sold 24,000 shares of Theravance Biopharma stock in a transaction dated Monday, June 2nd. The stock was sold at an average price of $11.00, for a total value of $264,000.00. Following the transaction, the senior vice president owned 336,918 shares in the company, valued at approximately $3,706,098. The trade was a 6.65% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 6.90% of the company's stock.

Hedge Funds Weigh In On Theravance Biopharma

A number of hedge funds have recently modified their holdings of TBPH. Assenagon Asset Management S.A. bought a new position in shares of Theravance Biopharma during the second quarter valued at approximately $264,000. Rhumbline Advisers increased its position in Theravance Biopharma by 3.8% during the 1st quarter. Rhumbline Advisers now owns 62,254 shares of the biopharmaceutical company's stock valued at $556,000 after purchasing an additional 2,293 shares during the period. Acadian Asset Management LLC raised its holdings in Theravance Biopharma by 121,993.7% in the 1st quarter. Acadian Asset Management LLC now owns 174,594 shares of the biopharmaceutical company's stock worth $1,554,000 after purchasing an additional 174,451 shares in the last quarter. Jane Street Group LLC raised its holdings in Theravance Biopharma by 169.2% in the 1st quarter. Jane Street Group LLC now owns 140,884 shares of the biopharmaceutical company's stock worth $1,258,000 after purchasing an additional 88,540 shares in the last quarter. Finally, Park West Asset Management LLC lifted its position in shares of Theravance Biopharma by 0.6% in the 1st quarter. Park West Asset Management LLC now owns 1,804,244 shares of the biopharmaceutical company's stock worth $16,112,000 after purchasing an additional 11,256 shares during the period. Hedge funds and other institutional investors own 99.10% of the company's stock.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.